Virology
TWiV 881: 50 ways to zap your virus
By Vincent Racaniello | | This Week in Virology
TWiV describes the identification of a monoclonal antibody that provides broad protection against a variety of hantaviruses, and development of an oral remdesivir-like antiviral that ameliorates viral disease in mice.
TWiV 880: COVID-19 clinical update #107 with Dr. Daniel Griffin
By Vincent Racaniello | | This Week in Virology
In COVID-19 clinical update #107, Daniel Griffin discusses Moderna vaccine results in children, hospitalization by ethnicity, BA.2 severity in children, placentitis and thrombohematoma during pregnancy, predictive value of symptoms for diagnosis, Evusheld activity against BA.1 and BA.2, Remdesivir resistance, Ivermectin with and without strongyloidiasis, inhaled ciclesonide, home telemonitoring, pulse oximetry for remote monitoring, effectiveness of anti-platelet therapy, and deaths in Zambia.
TWiV 879: Indolent, resistant, and losing our TMPRSS
By Vincent Racaniello | | This Week in Virology
TWiV reviews the emergence of remdesivir-resistant SARS-CoV-2 during treatment of a persistently infected immunocompromised patient, and how altered TMPRSS2 utilization by the Omicron variant influences infectivity and fusion.
Q&A with A&V Livestream 3/23/22
By Vincent Racaniello | | Q&A with A&V
Virologists Amy Rosenfeld and Vincent Racaniello answer your COVID-19 questions (or any virus questions) on this livestream of 3/23/22 at 8:30 PM eastern US.
TWiV 878: Shape matters sometimes
By Vincent Racaniello | | This Week in Virology
TWiV revisits chronic wasting disease of cervids and the ability of the prions to infect meadow voles and raccoons, and the suggestion that stochastic assembly of influenza virus particles may play a role in phenotypic diversity.
TWiV 877: COVID-19 clinical update #106 with Dr. Daniel Griffin
By Vincent Racaniello | | This Week in Virology
In COVID-19 clinical update #106, Daniel Griffin covers failure of ivermectin to improve hospitalization, increased hospitalization of children with Omicron, seroconversion of children versus adults, effectiveness of Pfizer mRNA vaccine in children, high vaccine effectiveness in Finland against Omicron, distinct long COVID clinical phenotypes, and estimating worldwide excess mortality.
David Tuller
Trial By Error: Claims Built on Fraudulent Trials Should Be Ignored
By David Tuller, DrPH When researchers cite fraudulent studies in support of their claims, it is best not to take anything they write at face value. That is certainly the case with a recent paper titled “Persistent physical symptoms not explained by structural abnormalities or disease processes: a primary care approach to promote recovery,” published …
Trial By Error: Claims Built on Fraudulent Trials Should Be Ignored Read More »
Trial By Error: Is Professor Crawley Retired from Bristol, or Isn’t She?
By David Tuller, DrPH Professor Esther Crawley, the methodologically and ethically challenged pediatrician and former grant queen at the University of Bristol, retired from medical practice and, apparently, from academia at some point in the recent past. So why does her name still appear on websites as if she were an active participant in research …
Trial By Error: Is Professor Crawley Retired from Bristol, or Isn’t She? Read More »
Trial By Error: Norway Disability Case Exposes Flaws in Draft Guideline for “Long-Term Fatigue–including ME/CFS”
By David Tuller, DrPH A recent disability case in Norway provides a good example of why the draft of a new guideline for “long-term fatigue—including ME/CFS” is so problematic. As I reported last week, the draft guideline, produced by the Norwegian Directorate of Health*, generally favors the biopsychosocial approach. The guideline offers few specifics about …
Trial By Error: Why is Professor Crawley Still on the COFFI Steering Committee?
By David Tuller, DrPH Several years ago, the leaders of the biopsychosocial ideological brigades decided to create the Collaborative On Fatigue and related symptoms Following Infection, or COFFI. According to its website, COFFI’s “overarching aim” is “to investigate factors influencing the development of long-term symptoms (in particular fatigue) following certain infectious diseases.” Akershus University Hospital …
Trial By Error: Why is Professor Crawley Still on the COFFI Steering Committee? Read More »
Trial By Error: Aussie GPs Still Push Graded Exercise Therapy
By David Tuller, DrPH When I was in Australia for the first time in 2018, it was clear that the country’s general practitioners were fervent supporters of the biopsychosocial ideology when it came to ME/CFS. That hasn’t changed, according to a recent exchange of views published in the Australian Journal of General Practice. The debate …
Trial By Error: Aussie GPs Still Push Graded Exercise Therapy Read More »
Trial By Error: Dutch Agency Funds CBT Training Program Based on Flawed Long COVID Trial
By David Tuller, DrPH Here is how bullshit replicates itself in today’s medical world: Conduct a flawed trial, declare success despite serious questions, then develop health policy based on these hyped-up claims. ZonMW, a major Dutch healthcare funding agency, is supporting a new program led by Professor Hans Knoop, a longtime supporter of the fraudulent …
Trial By Error: Dutch Agency Funds CBT Training Program Based on Flawed Long COVID Trial Read More »